Background: Hyperviscosity of blood secondary to polycythemia results in increased resistance
to blood flow and decrease in delivery of oxygen.
Objective: To evaluate whether serum endocan, NSE and IMA levels can be compared in terms of
endothelial injury/ dysfunction and neuronal damage in term neonates with polycythemia who underwent
Methods: 38 symptomatic polycythemic newborns having PET and 38 healthy newborns were included
in the study. Blood samples for endocan, NSE and IMA were taken at only postnatal 24
hours of age in the control group and in polycytemia group just before PET, at 24 and 72 hours after
Results: The polycythemia group had higher serum endocan(1073,4 ± 644,8 vs. 378,8 ±
95,9ng/ml; p<0.05), IMA(1,32 ± 0,34 vs.0,601 ± 0,095absorbance unit; p<0.05) and NSE(44,7 ±
4,3 vs. 26,91 ± 7,12μg/l; p<0.05) levels than control group before the PET procedure. At 24 hours
after PET, IMA(0,656 ± 0,07 vs. 0,601 ± 0,095absorbance unit; p<0.05) and endocan(510,9 ±
228,6 vs. 378,8 ± 95,9ng/ml; p<0.05) levels were closer to the control group, being still statistically
significant higher. NSE levels decreased to control group levels having no difference between the
PET and control groups at 24 hours after PET (28,98 ± 6,5 vs. 26,91 ± 7,12μg/l; p>0.05). At 72
hours after PET the polycythemia and control groups did not differ statistically for IMA, endocan
and NSE levels (p>0.05).
Conclusion: Serum endocan and IMA levels can be used as a biomarker for endothelial damage/
dysfunction and tissue hypoxia in infants with symptomatic polycytemia.